Avondale Wealth Management’s Biogen BIIB Stock Holding History

Avondale Wealth Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-110	Closed	-$25.5K	–	115
2024 Q2	$25.5K	Hold	110	–	–	0.02%	100
2024 Q1	$23.7K	Hold	110	–	–	0.02%	103
2023 Q4	$28.5K	Hold	110	–	–	0.02%	94
2023 Q3	$28.3K	Hold	110	–	–	0.02%	96
2023 Q2	$31.3K	Hold	110	–	–	0.03%	93
2023 Q1	$30.6K	Hold	110	–	–	0.03%	93
2022 Q4	$30.5K	Hold	110	–	–	0.03%	89
2022 Q3	$29K	Hold	110	–	–	0.03%	85
2022 Q2	$22K	Hold	110	–	–	0.03%	90
2022 Q1	$23K	Hold	110	–	–	0.03%	88
2021 Q4	$26K	Buy	+110	New	+$28.3K	0.03%	83

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Avondale Wealth Management's BIIB Position: Q3 2024 in Review

Avondale Wealth Management sold out of Biogen (BIIB) in Q3 2024, closing a stake of 110 shares — an estimated $25.5K sold.

Avondale Wealth Management first reported a position in BIIB in Q4 2021 and held it in 11 quarters. The position peaked at $31.3K in Q2 2023. 917 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

Avondale Wealth Management reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
Avondale Wealth Management sold 110 Biogen shares in Q3 2024, an estimated $25.5K.
Avondale Wealth Management first reported a position in Biogen in Q4 2021 and held it in 11 quarters.
Avondale Wealth Management's Biogen position peaked at $31.3K in Q2 2023.
917 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Avondale Wealth Management's 13F filing for Q3 2024, filed 10 Oct 2024.